October 27, 2017 4:35 pm FDA Rejects Drug For Duchenne Muscular Dystrophy The U.S. Food and Drug Administration rejects application for ataluren, a protein therapy, which families claim has helped slow the progression of Duchenne muscular dystrophy in their children. Wake Up to Something Good 2:06 Advances in hearing aid technology 1:17 Momentous Institute offering free training to help navigate mental health crisis 0:40 Midlothian teen gets ‘NFL Draft' experience 2:11 New app helps dementia caregivers focus on their own health 2:19 Grandfather of seven shares how he survived a rare heart event
